A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ono Pharma USA Inc
• Treatments: Ceralifimod

Criteria

Inclusion Criteria:

• Adult male or female aged 18-55 years inclusive at screening

• Patients who have a definite diagnosis of relapsing-remitting Multiple Sclerosis

Exclusion Criteria:

• Multiple Sclerosis course other than relapsing-remitting multiple sclerosis

• History of malignancy

• History of clinically significant chronic disease of the immune system (other than Multiple Sclerosis)

• Inability to undergo Gd-enhanced MRI scans

• Diagnosis of diabetes mellitus (type I or type II)